Several recent reports have demonstrated that small activating dsRNA [double-stranded RNA; saRNA (small activating dsRNA)] complementary to promoter regions can up-regulate gene expression in mammalian cells, a phenomenon termed RNAa (RNA activation). However, the mechanism of RNAa remains obscure with regard to what is the target molecule for promoter-targeted saRNA and what are the proteins involved in this process. p21
INTRODUCTION
RNAi (RNA interference) is a natural cellular process in which small RNAs, such as siRNA (short interfering RNA) and microRNA target homologous mRNA sequences to degrade the mRNA or inhibit their translation leading to post-transcriptional gene silencing [1] [2] [3] . Previous studies have also found that small RNAs complementary to gene promoters cause TGS (transcriptional gene silencing) by modulating epigenetic events associated with the target promoter [4] [5] [6] [7] [8] . More recently, we and others reported that dsRNAs (double-stranded RNAs) complementary to target sequences within gene promoters can induce gene expression [9] [10] [11] [12] [13] [14] [15] , a phenomenon referred to as RNAa (RNA activation). These dsRNAs, termed saRNAs (small activating RNAs), are 21 nucleotide duplexes with a structure identical to siRNA that targets mRNA sequences. RNAa requires the AGO2 (argonaute 2) protein to regulate RNAi, but possesses unique kinetics characterized by a delay in the start of gene activation which subsequently lasts for over 10 days [16] . These observations suggest that RNAa is a mechanism distinct from RNAi. However, the molecular mechanism of RNAa remains elusive with regard to questions such as what is the target molecule of saRNA and what proteins participate in this process.
hnRNPs [heterogeneous nuclear RNPs (ribonucleoproteins)] are families of RNA-binding proteins, which reside predominantly in the nucleus to form the core of the RNP complex that associates with nascent transcripts in eukaryotic cells [17] . The protein components of the RNPs participate in a number of cellular functions, including DNA maintenance and recombination, transcription and processing of primary transcripts, and nuclear export, subcellular localization, translation and stability of mature mRNA [18] [19] [20] . Previously hnRNPs have been shown to associate with small regulatory RNAs and function in a wide range of biological processes. For example, a special RNP could transport siRNAs into the nucleus in order to facilitate nuclear RNAi in Caenorhabditis elegans [21] . The K subfamily of hnRNPs (hnRNP-k) are involved in transcriptional regulation mediated by promoter-targeted dsRNA or saRNA in human cells [22] . p21 WAF1/CIP1 (p21) [CDKN1A (cyclin-dependent kinase inhibitor 1A)] is a well-characterized cyclin-dependent kinase inhibitor that belongs to the Cip/Kip family of cyclin-dependent kinase inhibitors and is a key regulator of the cell cycle as well as cell death, DNA repair, senescence, aging and as a barrier in reprogramming of iPSs (induced pluripotent stem cells) [23, 24] . Transcription regulation mediated by multiple transcription factors (p53, Sp1/Sp3 and c-Myc) is considered to play a critical role in p21 expression and activity [25] [26] [27] . In addition, recent work suggests that post-transcriptional control of p21 is equally important. For instance, many ubiquitin ligases and protein kinases regulate the stability and cellular localization of p21 protein, thereby regulating its activity [28, 29] .
By targeting the p21 gene promoter region, we demonstrated that a saRNA could induce cell-cycle arrest and apoptosis via up-regulation of the expression of p21 in human prostate and bladder cancer cells [9, 10] . In the present study, we performed detailed analysis of RNAa using the saRNA and showed that the saRNA could associate specifically with its intended target on the promoter and interacts with hnRNPA2/B1, a subfamily of hnRNPs. Knockdown of hnRNPA2/B1 could block the saRNAmediated p21 induction. These findings reveal that as a core protein in RNAa process, hnRNPA2/B1 facilitates recognition of the p21-specific promoter by the saRNA.
EXPERIMENTAL dsRNA design and synthesis
dsRNAs were designed and synthesized as described previously [9] . A 21 nucleotide dsRNA targeting the p21 promoter at sequence position − 322 relative to the TSS (transcription start site) (dsP21-322) was used to activate p21 expression [dsP21-322-S (sense), 5 -CCAACUCAUUCUCCAAGUAdTdT-3 and dsP21-322-AS (antisense), 5 -UACUUGGAGAAUGAGUUGGdTdT-3 ]. A 21 nucleotide dsRNA lacking significant homology to all known human sequences (dsControl) was used as a non-specific control [dsControl-S (sense), 5 -ACUACUGAGUGACAGUAGAdTdT-3 and dsControl-AS (antisense), 5 -UCUACUGUCACUCAGUAGUdTdT-3 ]. The siRNAs sequences of hnRNPA2/B1 were: sense, 5 -GGAACAGUUCCGUAAGCUCdTdT-3 and antisense, 5 -GAGCUUACGGAACUGUUCCdTdT-3 . siCon (a scrambled dsRNA based on the mRNA sequence of hnRNPA2/B1) was also synthesized and used as a negative control. The synthetic dsRNAs were manufactured by Ribobio.
Plasmids and antibodies
pCI-FLAG-hnRNPA2/B1 plasmid (a gift from Professor Christopher Smith, University of Cambridge, Cambridge, U.K.) [31] . 
Cell culture and transfection
PC-3 (A.T.C.C.) cells were maintained in RPMI 1640 medium supplemented with 10 % FBS (fetal bovine serum), 2 mM L-glutamine, penicillin (100 units/ml) and streptomycin (100 μg/ml) in a humidified atmosphere of 5 % CO 2 maintained at 37
• C. The day before transfection cells were plated in six-well plates or 150-mm culture dishes (Costar) without antibiotics at a density of 30-40 %. Transfections of all RNA duplex oligonucleotides were carried out by using Entranster-R (Engreen) transfection reagent according to the manufacturer's recommendations.
Nucleic acid extraction and protein expression
Total cellular RNAs were isolated with the TRIzol reagent (Invitrogen). Genomic DNA was isolated by using QIAamp DNA Blood Maxi kit (Qiagen). The pCI-FLAG-hnRNPA2/B1 plasmid was transcribed/translated hnRNPA2/B1 protein in vitro by using TNT ® T7 Quick Coupled Transcription/Translation system (Promega) according to the manufacturer's recommendations.
RNA analysis
Expression of p21, hnRNPA2/B1 and non-coding transcripts overlapping the p21 promoter was evaluated by semi-quantitative RT (reverse transcription)-PCR or qRT-PCR (quantitative RT-PCR). Each RNA sample was treated with RNase-free DNase I (Qiagen) to remove any potential DNA contamination. Samples of 2 μg of total RNA were used for cDNA synthesis using SuperScript reverse transcriptase (Invitrogen) and oligo(dT) primers or random primers. qRT-PCR was performed to quantify gene expression by using Platinum ® SYBR ® Green qPCR SuperMix-UDG (Invitrogen) and an Stratagene Mx3000 TM sequence detection system (Stratagene). Semi-quantitative RT-PCR was also used to evaluate gene transcript expression. The specific primer sequences used are listed in Supplementary Table S1 (at http://www.BiochemJ.org/bj/447/bj4470407add.htm).
RACE (rapid amplification of cDNA ends)
5 RACE was performed using the GeneRacer kit (Invitrogen). cDNA samples from PC-3 cells were prepared according to the manufacturer's protocol. The 5 -end of cDNA was amplified through two nested PCR steps using Platinum Taq DNA Polymerase High Fidelity (Invitrogen). Appropriate primer sets (Supplementary Table S1 ) were used to maximize detection of transcripts and reduce the likelihood of bias from any one primer set. After gel purification, the PCR products were cloned into a pMD18T vector and sequenced (Invitrogen). We sequenced several clones from at least two independent experiments to confirm the results.
ChIP assay
The ChIP assays were performed by using a ChIP assay kit (catalogue number 17-371, Millipore) according to the manufacturer's instructions. A total of 3.5×10 6 cells were used for one separate immunoprecipitation. The RNase inhibitor RNasin (50 units/ml final) was added to each buffer used in this assay to avoid degradation of duplex RNAs. The following antibodies were used for immunoprecipitations: anti-biotin, anti-AGO2, antihnRNPA2/B1, anti-(RNA Pol II), anti-H3m3K4 (histone H3 trimethylated at Lys 4 ), anti-H3acK9 and normal mouse IgG. A total of 5 μg of each of the appropriate antibody were used for each ChIP. Immunoprecipitated DNA was reverse cross-linked, purified and analysed by real-time PCR or semi-quantitative PCR. The primers used are described in Supplementary Table S1 .
Immunopurification, silver staining and MS PC-3 cells were transfected with modified dsP21-322-S-3 Bio or dsControl-S-3 Bio. At 72 h after transfection, cellular lysates were prepared by incubating the cells in 0.5 % Nonidet P-40 lysis buffer containing protease inhibitor cocktail (1 μl/ml final) and RNase inhibitor RNasin (50 units/ml final) in DEPC (diethyl pyrocarbonate). Streptavidin affinity columns were prepared (Pierce) following the manufacturer's suggestions. Cell lysates were obtained from 5×10 8 cells, then added to the column and allowed to enter the resin bed. The bottom and top caps were sequentially replaced and incubated at room temperature (22 • C) for 2 h. After binding, the column was washed with the cold lysis buffer. GdnHCl [guanidine hydrochloride; 8 M, pH 1.5 (Pierce)] was applied to the column to elute the biotinylated dsRNA-protein • C with rotation, the beads were briefly incubated and washed three times with biotin blocking solution (2 mM biotin blocking buffer, pH 7.2, Pierce) containing the RNase inhibitor RNasin (50 units/ml final). Subsequently, the beads were washed three times with the biotinylated pull-down binding buffer and resuspended in 0.4 ml of the biotinylated pull-down binding buffer before adding 5 μl of in vitro transcribed/translated hnRNPA2/B1 for 2 h at 4
• C with rotation. The beads were then washed three times with 0.5 ml of wash buffer (50 mM sodium acetate, pH 5.0). The bound proteins were eluted by boiling in 25 μl of loading buffer and resolved on SDS/PAGE (12% gel). Immobilized Streptavidin and each buffer used in the biotin pull-down assay was consistent with Pull-Down Biotinylated Protein-Protein Interaction kit (Pierce). The RNase inhibitor RNasin (50 units/ml final) was added to each buffer to avoid degradation of duplex RNAs.
Co-IP and WB
Cultured PC-3 cells were washed twice with ice-cold PBS containing Protease Inhibitor cocktail (1 μl/ml final concentration) and the RNase inhibitor RNasin (50 units/ml final). Then cellular lysates were prepared by incubating the cells in lysis buffer [50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.5 % Nonidet P40 and 2 mM EDTA) containing protease inhibitor cocktail and the RNase inhibitor in DEPC for 30 min at 4
• C, followed by centrifugation at 14 000 g for 15 min at 4
• C. The protein concentration of the lysates was determined in the supernatant fraction by using the BCA (bicinchoninic acid) protein assay kit according to the manufacturer's protocol (Pierce). For IP, 500 μl of protein was incubated with 60 μl of immobilized Streptavidin (Pierce) for 12 h at 4
• C with constant rotation; 60 μl of 50% Protein A or G agarose beads were then added and the incubation was continued for an additional 2 h at 4
• C with rotation. The beads were then washed five times using the lysis buffer. Between washes, the beads were collected by centrifugation at 500 g for 1 min at 4
• C. The precipitated proteins were eluted by resuspending the beads in 2× SDS/PAGE loading buffer and boiling for 5 min. The resultant materials from IP or cell lysates were resolved by SDS/PAGE (10 % gels) and transferred on to nitrocellulose membranes (Millipore). For WB, membranes were incubated with appropriate antibodies for 1 h at room temperature (22 • C) or overnight at 4
• C followed by incubation with a secondary antibody. Immunoreactive bands were visualized using WB Luminol reagent (Santa Cruz Biotechnology) according to the manufacturer's instructions.
RESULTS

Characterization of the p21 TSS and promoter transcripts
Two models of action for RNAa have been proposed, with one stating that transcriptional activation is realized by targeting noncoding transcripts that overlap the target promoter [14, 22] , and the other suggesting that saRNA directly targets and binds promoter DNA. To determine whether there are non-coding transcripts originating from, or overlapping with, the p21 promoter, we isolated total cellular RNA from PC-3 (prostate adenocarcinoma) cells which respond to RNAa of p21, and converted the resulting RNA into cDNA using random hexamer primers. We then detected potential p21 promoter transcripts by RT-PCR using several primer sets that cover different regions on the p21 promoter ranging from − 917 to − 127 ( Figure 1A ). Primers that amplify the p21 mRNA sequence between + 48 and + 140 served as a positive control ( Figures 1A and 1B) . As shown in Figure 1 (B), none of the p21 promoter primer sets amplified the PCR products from the cDNA samples, whereas they amplified the expected products from genomic DNA which was used as controls for primer amplification efficiency. Designing saRNA requires accurate identification of the TSS of the target gene. We used RACE to determine the TSS of p21 mRNA in PC-3 cells. After cloning and sequencing of the RACE products, we confirmed that the TSS for p21 mRNA is almost identical with its GenBank ® sequence (accession number NM_000389.4; Supplementary Figure S1 at http://www. BiochemJ.org/bj/447/bj4470407add.htm). Previous studies have identified a saRNA target on the p21 promoter at position − 322 relative to the TSS and saRNA corresponding to that location (dsP21-322) causes robust p21 activation in different human cells [9, 12] . It is possible that saRNA bound to the promoter may serve as a RNA primer to prime RNA transcription from the target site by recruiting the RNA Pol II complexes. To test such a possibility, we transfected dsP21-322 into PC-3 and mapped the 5 -end of p21 mRNA by 5 RACE assay before and after dsP21-322 transfection. As shown in Figure 1 (C), we failed to observe extended or new 5 -end of p21 mRNA in dsP21-322 transfected cells compared with the untransfected cells. These data indicate that p21 activation by promoter targeting is not due to a RNA priming mechanism.
dsP21-322 interacts with p21 promoter saRNA activity requires its complementarity to sequences within promoter DNA [9] [10] [11] . Given that we were unable to detect any RNA transcript at the p21 promoter, we speculated that dsP21-322 may interact directly with p21 promoter DNA. To explore such a possibility, we performed a ChIP assay to pull down DNA associated with biotinylated p21 promoter-targeted saRNAs which were transfected into PC-3 cells. We synthesized modified dsRNAs molecules derived from dsP21-322 or dsControl that were covalently linked to biotin either at the 3 -end of the sense (Figure 2A ). These differently modified saRNAs allowed us to determine which strand of the saRNA molecule interacts with the promoter DNA. Before they were used in ChIP assay, we first tested RNAa activity of these biotinylated dsP21-322 in PC-3 cells. As shown in Figures 2(B) and 2(C), linking a biotin group to the 5 -end of the antisense strand of dsP21-322 (dsP21-322-AS-5 Bio) abolished activation of p21, whereas biotin labelling at the other three sites did not significantly affect dsP21-322 activity. This result is consistent with previous observations [9, 16] . Then, using a well-characterized antibody that recognizes biotin protein, we performed a ChIP assay to evaluate the potential binding of dsP21-322 at the p21 promoter after individually transfecting the three activating biotinylated dsP21-322 RNAs into PC-3 cells for 72 h. DNA samples pulled down with the anti-biotin antibody were amplified by PCR using several primer sets capable of amplifying the target p21 promoter at different locations ( Figures 3A and 3C) . One set of primers amplifying the p21 promoter from − 1309 bp to − 1150 bp relative to the TSS served as a negative control. As shown in Figure 3 , all three of the biotin-labelled dsP21-322 RNAs pulled down promoter proximal DNA (from − 395 to − 127) more effectively than the dsControl RNA did (Figures 3B  and 3D ). In contrast, there was no difference in the binding of dsP21-322 and dsControl RNAs to the DNA upstream of the p21 promoter that served as a negative control ( − 1309 to − 1150). The moderate ability of dsControl RNAs to associate with the p21 promoter does not activate p21 expression, which implies that recognition to the target sequence alone for dsRNAs is not sufficient for gene activation, These results indicate that promotertargeted dsRNA can directly interact with its target promoter.
Recruitment of RNA Pol II and AGO2 proteins at the dsP21-322 target site or p21 TSS
To determine whether enrichment of RNA Pol II at the chromosomal DNA of p21 was associated with dsP21-322- ChIP assays were performed by using an anti-biotin antibody to pull down DNA associated with biotinylated saRNA in PC-3 cells transfected at 50 nM concentrations of the indicated dsControl or activating dsP21-322 for 72 h. The resulted DNA was amplified by qPCR using the above corresponding primer sets and normalized to the input levels. The input was the cellular lysates prior to treatment with antibody. IgG was used as a negative control antibody. Results are means + − S.D. calculated from three independent transfection experiments with triplicate qPCR measurements for each. Statistical significance was tested using a paired Student's t test.
induced gene expression, we performed ChIP assays using an antibody specific against RNA Pol II and observed that activated dsP21-322 enhanced the association of RNA Pol II with the dsP21-322 target site ( Figure 4C ) and p21 TSSs ( Figure 4D ). We also found RNA Pol II enrichment at the region upstream from the dsP21-322 target site was increased after treatment with dsP21-322 ( Figure 4A ). These results indicate that up-regulation of p21 mediated by dsP21-322 occurs at the transcriptional level.
AGO2 has been shown to be involved in several models of dsRNA-mediated gene activation as demonstrated by both loss-offunction study and ChIP assay [14, 22, 32, 33] . To examine whether introduction of activating dsP21-322 could increase enrichment of AGO2 protein at the p21 promoter, we also performed a ChIP assay using the anti-AGO2 antibody. Consistent with previous reports [14, 22, 32, 33] , AGO2 enrichment was evident at the dsP21-322 target site after transfection of dsP21-322. No ChIP product was observed after transfection with dsControl ( Figures 4F and 4G ). This data indicates that dsP21-322 recruits AGO2 to its target site.
A loss of H3K27 trimethylation (H3K27me3), which is a transcription-suppressive chromatin mark, has observed at the p21 promoter after treatment with dsP21-322 [34] . To further determine the potential role of other histone modification marks in the activation of p21 expression, we chose H3K9 acetylation (H3acK9) which had been identified to be involved in another model of RNAa [10] . However, no significant changes were detected at the dsP21-322 targeted site or p21 transcription start sites after transfecting dsP21-322 into PC-3 cell (Supplementary Figure S2 at http://www.BiochemJ.org/bj/447/ bj4470407add.htm). This might reflect that H3acK9 is not a dominant regulatory factor for the p21 gene.
Association of hnRNPs with dsP21-322 in vivo
We have demonstrated that dsP21-322 specifically binds to the p21 promoter. Characterizing the proteins involved in modulating gene expression by promoter-bound dsP21-322 is essential for understanding the mechanism of RNAa. We employed affinity purification and MS to identify proteins associated with dsP21-322. In these experiments, biotinylated dsP21-322 (dsP21-322-S-3 Bio) or dsControl (dsControl-S-3 Bio) were transfected into PC-3 cells for 72 h. Cellular extracts were harvested and subjected to affinity purification using immobilized Streptavidin-affinity columns. After exhaustively washing, the bound proteins were eluted from each column, resolved by SDS/PAGE electrophoresis and then visualized by silver staining. The protein bands on the gel were retrieved and analysed by LC-MS/MS. Compared with the dsControl (Figure 5A ), our results revealed that dsP21-322 co-purified with several proteins, including pyruvate carboxylase precursor, lamin A, vimentin, nucleophosmin 1 and histone cluster 1 ( Figure 5A ). Of importance, three subfamilies of hnRNPs, including hnRNPA2/B1, hnRNPC1/C2 and hnRNPA1, were also identified in the dsP21-322-containing protein complex, suggesting that dsP21-322 is associated with hnRNPs in vivo. Further details regarding the above identified proteins are shown in Supplementary Table S2 (at http://www.BiochemJ.org/bj/447/bj4470407add.htm). The identification of four matching peptides from hnRNPA2/B1 prompted us to study further the functional relevance of its interaction with dsP21-322.
Interactions between hnRNPA2/B1 and dsP21-322 in vivo and in vitro
In order to confirm the in vivo association between hnRNPA2/B1 and dsP21-322, PC-3 cell lysates were prepared after treatment with biotinylated dsP21-322 (dsP21-322-S-3 Bio) or dsControl (dsControl-S-3 Bio) and co-IP assays were performed with immobilized Streptavidin against biotin. The immunoprecipitates were then analysed by immunoblotting with an anti-hnRNPA2/B1 antibody. As shown in Figure 5 (B), hnRNPA2/B1 was efficiently co-immunoprecipitated with dsP21-322, whereas no band was detected with the dsControl. To confirm further a direct interaction between hnRNPA2/B1 and dsP21-322, biotin pulldown experiments were performed. We incubated in vitro transcribed/translated hnRNPA2/B1 protein with biotinylated dsP21-322 (dsP21-322-S-3 Bio) or dsControl (dsControl-S-3 Bio). The binding of hnRNPA2/B1 to the dsRNAs was collected through immobilized Streptavidin and analysed by immunoblotting using an anti-hnRNPA2/B1 antibody. As shown in Figure 5 (C) it was found that hnRNPA2/B1 could interact with the dsP21-322 rather than the dsControl in vitro.
Association of hnRNPA2/B1 with the dsP21-322 target site on p21 promoter
We have shown that dsP21-322 could bind to the p21 promoter and also interact with hnRNPA2/B1, suggesting that hnRNPA2/B1 probably also associates with the p21 promoter. To test such a possibility, we performed a ChIP assay to pull down DNA associated with hnRNPA2/B1 using an anti-hnRNPA2/B1 antibody in PC-3 cells transfected with dsP21-322. We then amplified the DNA using primers that span the dsP21-322 target site ( Figure 6A ). As shown in Figure 6 (B), the p21 promoter DNA was co-immunoprecipitated with hnRNPA2/B1, suggesting that hnRNPA2/B1 could be associated with the p21 promoter and play a role in p21 transcription. However, unlike our observation in RNA Pol II and AGO2, little significant enhancement of hnRNPA2/B1 at the p21 target promoter was detected in dsP21-322-transfected cells compared with the dsControl-transfected cells ( Figure 6C ). These data indicate that hnRNPA2/B1 binds to dsP21-322 and localizes to the dsP21-322 target site.
hnRNP A2/B1 is required for dsP21-322-induced p21 expression
To test whether hnRNPA2/B1 is an transcriptional co-activator and if its expression is required in RNAa, we performed a loss-of-function study of hnRNPA2/B1. We transfected PC-3 cell with siRNAs targeting hnRNPA2/B1 mRNA in combination with dsP21-322. The effect of reduced hnRNPA2/B1 expression on the activity of dsP21-322 was evaluated by RT-PCR and immunoblotting after 72 h and 96 h respectively. As shown in Figure 7 (A), inhibition of hnRNPA2/B1 expression prevented p21 gene induction by dsP21-322. In the presence of basal levels of hnRNPA2/B1, the addition of dsP21-322 led to a 5.5-fold increase in p21 mRNA expression, whereas when hnRNPA2/B1 expression was repressed dsP21-322 transfection only produced a 2.1-fold induction in p21 expression compared with the mock-transfected cells ( Figure 7B ). We also observed a similar attenuation of dsP21-322-mediated activation of p21 protein expression when hnRNPA2/B1 was knocked down ( Figure 7C ). These results suggest that hnRNPA2/B1 is an important component of the RNAa effector complex.
DISCUSSION
Targeting promoter sequences using small duplex RNA mediated by AGO has the potential to influence transcription of target genes [9] [10] [11] [35] [36] [37] . However the mechanism by which promotertargeted dsRNA modulates transcription remains elusive. In the present study we showed that p21 promoter-targeted saRNA can specifically recognize and interact with the p21 promoter and induce p21 expression. Such targeting causes increased occupancy of RNA Pol II and AGO2 protein at the dsP21-322 target site which is close to the p21 TSS. We also identified hnRNPA2/B1 as a putative effector protein required for RNAa.
For traditional RNAi, only the antisense strand of the siRNAs can directly bind to mRNA and induce cleavage of their target transcripts [30, 38] . For the targeting of promoters it is unclear which strand guides RNAa activity. In the present study we showed that either biotinylated sense strand or antisense strand of the dsP21-322 could interact with the p21 promoter and up-regulate p21 expression, suggesting a potentially important mechanistic difference between the two processes in cells. Similar to the present study, it has been demonstrated that activation of the PR (progesterone receptor) and LDLR (low-density lipoprotein receptor) genes by targeting promoter sequences with saRNA is facilitated through interacting with a non-coding antisense transcript overlapping the promoter [14, 22] . In these cases, the sense strand in the saRNA duplex triggers RNAa activity. In another report, in which PR expression was induced by targeting sequences beyond the 3 -termini of mRNA with saRNA [32] , implying that RNAa activity is mediated by the antisense strand in this saRNA duplex. As such, both the sense and antisense strand in the saRNA could serve as the guide and interact with the target.
RNA has long been known to hybridize to dsDNA [39] with high stability comparable with that of protein-DNA complexes [40] . It has been postulated that RNA hybridization with the promoter could facilitate the binding of template strand by RNA Pol II [41] . In the present study, specific promoters are recognized by the sense or antisense strand of the dsRNAs with the help of an AGO protein, the interaction between them after hybridization then acts as a recognition motif for directing RNA Pol II to the corresponding targeted promoters to mediate transcriptional regulation in human cells. A previous observation by Place et al. [11] indicated that the concurrent activation of E-cadherin and CSDC2 (cold shock domain containing protein C2) by miR-373 was specific for the microRNA target sites in both gene promoters and was associated with enrichment of RNA Pol II at targeted gene promoters [11] . Likewise, it has also been reported that signal-induced ncRNAs (non-coding RNAs) localized to the transcriptional regulatory regions of the CCND1 (cyclin D1) promoter can recruit and modulate the activities of RNA-binding co-regulators in response to DNA damage signals, causing genespecific repression [42] . These observations suggest that small RNAs recognition and interaction with gene promoters may be a natural and general mechanism for regulating gene transcription.
In contrast with the results of the present study, as mentioned above, there have been previous reports that non-coding transcripts serve as the molecular target of activating dsRNAs in human cells [14, 22, 32] , though these models of RNAa have also observed recruitment of RNA Pol II and AGO2 to gene promoters or TSSs. However, we did not detect any non-coding transcripts that overlap the p21 promoter from − 1000 bp to the TSS. Thus it is possible that saRNA interacts directly with its DNA target without the need for a third ncRNA as a docking molecule. This viewpoint is further supported by recent observations that chromatin-modifying complexes can be guided to specific genomic sites by many ncRNAs in mammalian cells [43, 44] . In addition studies from Morris and colleagues [34, 45] reported that dsP21-322-mediated gene activation of p21 is not, in theory, the result of direct promoter targeting, but rather is an offtarget effect of the dsP21-322 binding and cleaving an antisense RNA [EST (expressed sequence tag) Bx332409] overlapping p21 mRNA. However, Bx332409 is a rare EST which, according to NCBI Unigene database (http://www.ncbi.nlm.nih.gov/unigene/), is only expressed in human neuroblastoma. Li et al. [9] have also identified that non-specific IFN (interferon) response is not involved in dsP21-322-induced transcriptional activation. Our ChIP data demonstrated that saRNA could interact specifically with the p21 promoter. However, the result still cannot exclude the possibility that small nascent promoter transcripts originated from the saRNA target site serve as the target molecule of saRNA, even though our RACE and RT-PCR experiments failed to detect evidence for non-coding transcripts overlapping p21 promoter ( Figures 1B and 1C) . Transcriptome studies have revealed that over 70 % of gene promoters are overlapped by ncRNA transcripts [46, 47] . Therefore the role of ncRNA transcripts played in the process of dsP21-322-mediated gene expression requires further study.
A very interesting observation of the present study is that hnRNPA2/B1 plays an important role in saRNA-mediated gene activation. The present (Figures 4C and 4D ) and previous studies [22, 33] have found that AGO2 is a core effector protein for RNAa. Several lines of evidence from the present study suggest that hnRNPA2/B1 is another core protein critical for RNAa. First, hnRNPA2/B1 is enriched at the p21 gene promoter and its expression is required for efficient gene activation. Secondly, hnRNPA2/B1 interacts with dsP21-322. As one of the most abundant RNA-binding proteins, the interaction of hnRNPA2/B1 with RNA has been well established with the best-characterized hnRNPA2/B1-bound sequences being AU-rich sequences [48, 49] . dsP21-322 was designed to target an ATrich region of the p21 promoter, which explains the finding that hnRNPA2/B1 prefer to bind dsP21-322 rather than the dsControl ( Figure 5C ). Furthermore, the interaction between dsP21-322 and hnRNPA2/B1 facilitates the recognition of the p21-specific promoter by dsP21-322.
Previous findings have shown that hnRNPA2/B1could specifically associate with multiple promoter sequences and act as a common transcriptional co-activator [50] [51] [52] . A recent report has suggested that hnRNPA2/B1 associated with the tumoursuppressor gene ANXA7 (annexin A7) promoter sequences and up-regulated ANXA7 expression in PC-3 cells [53] . These findings support our result that hnRNPA2/B1 associates with the p21 promoter sequence and affects p21 transcriptional induction.
In the nematode, a special RNP is required to shuttle small siRNAs into nuclei in order to facilitate nuclear RNAi [21] and other researchers [54] have observed that small RNA actively migrate into the nuclear compartment of living human cells. However, we have not yet known whether hnRNPA2/B1 are also involved in trafficking dsP21-322 from the cytoplasm to the nucleus, and what are the functions of additional proteins associated with dsP21-322, including other hnRNPs (A1 and C1/C2), NPM1 [nucleophosmin (nucleolar phosphoprotein B23, numatrin)] and histone cluster1.
In summary, we have demonstrated that the p21 promotertargeting saRNA dsP21-322, in direct association with hnRNPA2/B1, enhances p21 expression through recognition and interaction with the specific sequence within the p21 promoter. Our findings thus provide new insight toward the mechanism for saRNAs-mediated gene activation and further support the view that RNAa is a distinct cellular mechanism by which small RNA participates in positive regulation of gene expression.
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